ReviewFrontiers in cardiovascular medicine2022
Clinical Characterization and Possible Pathological Mechanism of Acute Myocardial Injury in COVID-19.
Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Immune-endothelial-coagulation crosstalk as a driver of multi-organ dysfunction in severe viral pneumonia.Frontiers in immunology · 2026Review
- Interpretable machine learning identifies immune-inflammatory and immunothrombotic biomarkers for myocardial injury and mortality risk stratification in severe pneumonia with diverse infectious etiologies.Frontiers in cellular and infection microbiology · 2026Article
- A case-control study on the diagnostic role of Omega-3 fatty acid levels in erythrocyte membranes of critically ill patients.Scientific reports · 2025Article
- Cardioprotective effects of vaccination in hospitalized patients with COVID-19.Clinical and experimental medicine · 2024Article
- A study of hospitalized COVID-19 patients with AKI in a setting of multiracial developing country.BMC nephrology · 2024Article
- RNA m5C methylation modification: a potential therapeutic target for SARS-CoV-2-associated myocarditis.Frontiers in immunology · 2024Review
- Prevalence and prognostic implications of myocardial injury across different waves of COVID-19.Frontiers in cardiovascular medicine · 2024Article
- Interferons and interferon-related pathways in heart disease.Frontiers in cardiovascular medicine · 2024Review
- New-Onset Atrial Fibrillation in the Critically Ill COVID-19 Patients Hospitalized in the Intensive Care Unit.Journal of clinical medicine · 2023Review
- Pathomorphological Features of the Novel Coronavirus Disease in Patients with Systemic Amyloidosis.Biomedicines · 2023Article
- Mesenchymal Stem Cells in the Treatment of COVID-19.International journal of molecular sciences · 2023Review
- The molecular mechanism of cardiac injury in SARS-CoV-2 infection: Focus on mitochondrial dysfunction.Journal of infection and public health · 2023Article
- COVID-19 and atrial fibrillation: Intercepting lines.Frontiers in cardiovascular medicine · 2023Review
- Association between cardiovascular diseases and COVID-19 pneumonia outcome in Indonesia: a multi-center cohort study.Frontiers in medicine · 2023Article
- Screening for Myocardial Injury after Mild SARS-CoV-2 Infection with Advanced Transthoracic Echocardiography Modalities.Diagnostics (Basel, Switzerland) · 2022Article
- Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19.Molecular biomedicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a respiratory disease that can cause damage to multiple organs throughout the body. Cardiovascular complications related to COVID-19 mainly include acute myocardial injury, heart failure, acute coronary syndrome, arrhythmia, myocarditis. Among them, myocardial injury is the most common complication in COVID-19 hospitalized patients, and is associated with poor prognosis such as death and arrhythmias. There is a continuous relationship between myocardial injury and the severity of COVID-19. The incidence of myocardial injury is higher in critically ill patients and dead patients, and myocardial injury is more likely to occur in the elderly critically ill patients with comorbidities. Myocardial injury is usually accompanied by more electrocardiogram abnormalities, higher inflammation markers and more obvious echocardiographic abnormalities. According to reports, COVID-19 patients with a history of cardiovascular disease have a higher in-hospital mortality, especially in the elder patients. At present, the mechanism of myocardial injury in COVID-19 is still unclear. There may be direct injury of myocardial cells, systemic inflammatory response, hypoxia, prethrombotic and procoagulant state, myocardial interstitial fibrosis, interferon-mediated immune response and coronary artery plaque instability and other related factors, and angiotensin-converting enzyme-2 receptor may play a key role in the myocardial injury in COVID-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.